Intrahepatic cholangiocarcinoma remains a highly heterogeneous malignancy that has eluded effective patient stratification to date. The extent to which such heterogeneity can be influenced by individual driver mutations remains to be evaluated. Here, we analyzed genomic (whole-exome sequencing, targeted exome sequencing) and epigenomic data from 496 patients and used the three most recurrently mutated genes to stratify patients (IDH, KRAS, TP53, "undetermined"). Using this molecular dissection approach, each subgroup was determined to possess unique mutational signature preferences, comutation profiles, and enriched pathways. High-throughput drug repositioning in seven patient-matched cell lines, chosen to reflect the genetic alterations specific for each patient group, confirmed in silico predictions of subgroup-specific vulnerabilities linked to enriched pathways. Intriguingly, patients lacking all three mutations ("undetermined") harbored the most extensive structural alterations, while isocitrate dehydrogenase mutant tumors displayed the most extensive DNA methylome dysregulation, consistent with previous findings. Conclusion: Stratification of intrahepatic cholangiocarcinoma patients based on occurrence of mutations in three classifier genes (IDH, KRAS, TP53) revealed unique oncogenic programs (mutational, structural, epimutational) that influence pharmacologic response in drug repositioning protocols; this genome dissection approach highlights the potential of individual mutations to induce extensive molecular heterogeneity and could facilitate advancement of therapeutic response in this dismal disease. (HEPATOLOGY 2018; 68:949-963).
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Intrahepatic cholangiocarcinoma remains a highly heterogeneous malignancy that has eluded effective patient stratification to date. The extent to which such heterogeneity can be influenced by individual driver mutations remains to be evaluated. Here, we analyzed genomic (whole-exome sequencing, targeted exome sequencing) and epigenomic data from 496 patients and used the three most recurrently mutated genes to stratify patients (IDH, KRAS, TP53, "undetermined"). Using this molecular dissection approach, each subgroup was determined to possess unique mutational signature preferences, comutation profiles, and enriched pathways. High-throughput drug repositioning in seven patient-matched cell lines, chosen to reflect the genetic alterations specific for each patient group, confirmed in silico predictions of subgroup-specific vulnerabilities linked to enriched pathways. Intriguingly, patients lacking all three mutations ("undetermined") harbored the most extensive structural alterations, while isocitrate dehydrogenase mutant tumors displayed the most extensive DNA methylome dysregulation, consistent with previous findings. Conclusion: Stratification of intrahepatic cholangiocarcinoma patients based on occurrence of mutations in three classifier genes (IDH, KRAS, TP53) revealed unique oncogenic programs (mutational, structural, epimutational) that influence pharmacologic response in drug repositioning protocols; this genome dissection approach highlights the potential of individual mutations to induce extensive molecular heterogeneity and could facilitate advancement of therapeutic response in this dismal disease. (HEPATOLOGY 2018; 68:949-963).
I ntrahepatic cholangiocarcinoma (iCCA) incidence and mortality rates have increased globally over the last three decades, highlighting a growing clinical problem from what was once considered a rare orphan disease. (1, 2) The majority of iCCAs are sclerosing adenocarcinomas arising from cholangiocytes lining intralobular biliary ductules, as well as peribiliary glands of large intrahepatic bile ducts. (1, 3) While the causal biology of this cancer is largely unclear, known risk factors include chronic hepatitis B (HBV) or C viral infection with cirrhosis (4) ; chronic liver conditions, such as cholestasis, primary sclerosing cholangitis, (5) or liver fluke infestation (6) ; metabolic disorders, such as diabetes mellitus; and lifestyle or environmental factors, including alcohol consumption and smoking. (7) Liver resection remains the only curative treatment, a surgical procedure frequently precluded by early invasion of surrounding tissues. Even among 10%-30% patients eligible for resection, 50% recur within the first 12 months. Standard chemotherapy regimens (gemcitabine alongside platin-based compounds) for nonresectable and recurrent iCCA patients are purely palliative, achieving only a limited improvement in survival. (8) As most iCCAs are locally advanced or metastatic at presentation, patients have a dismal prognosis, with a 5-year survival rate that has persisted below 10% since the 1980s. (9) While no targeted therapy has been approved to date, fibroblast growth factor receptor 2 (FGFR2) inhibitors (e.g., BGJ398) may be the first to transform iCCA clinical management, displaying prospective efficacy (though of variable duration) in fusion-positive patients. (10) Similarly, future therapeutic advances will likely stem from further molecular stratification of iCCA patients, exposing oncogenic networks against which therapeutics may be strategized.
Recently, several cross-platform integrative analyses have identified broad CCA subgroups associated with specific clinical and molecular features. (11) (12) (13) However, interstudy comparison of these subgroups remains difficult, given that they are enriched by complex molecular characteristics identified in heterogeneous patient cohorts. Identification of single or few genomic alterations which influence downstream oncogenic networks could facilitate refinement of these established subgroups, as well as enhance prediction of therapeutic response to pharmacologic intervention against specific molecular backgrounds. As such, mutations in the genes isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) have been associated with unique genomic features (DNA hypermethylation, altered chromatin remodeler expression, increased copy number, and expression of mitochondrial genes), as well as sensitivity to dasatinib (14) and poly(adenosine diphosphate ribose) polymerase inhibitors. (15) The potential for individual driver mutations to influence diverse tumor networks is intriguing and remains to be evaluated for other recurrently mutated genes in iCCA, such as KRAS, TP53, and chromatin remodeling enzymes (e.g., ARID1A and BAP1).
Accordingly, we aimed to deconstruct the molecular programs of iCCA tumors associated with specific individual mutations. To this end, we grouped 496 patients into four subgroups where three were classified based on the most recurrent somatic mutations (IDH, KRAS, and TP53) and the remaining were based on wild-type status for these genes (referred to as the "undetermined" [Udt] group). This stratification approach unveiled distinct mutational signatures and comutations and pathway-enrichment and pharmacologic response profiles between subgroups, as well as suggesting an enhanced role of structural and epigenomic alterations in Udt group tumors. These findings uncover the potential of individual mutations to induce substantial downstream molecular heterogeneity, which could facilitate prediction of therapeutic
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sensitivities for iCCA patients using standard targeted genotyping.
Materials and Methods

PATIENTS AND SAMPLES
Data sets from a series of 496 iCCA patients were obtained for analysis (Supporting Fig. S1A ). In total, 165 fresh-frozen iCCAs were collected from surgically resected patients. All samples were immediately frozen in liquid nitrogen and stored at -808C pending genomic DNA isolation. The Danish Regional Ethics Committee and local authorities at contributing institutions approved the study. Written informed patient consent was obtained in accordance with regional regulation. All patient demographic and clinicopathological data were anonymized and are summarized in Supporting Tables S1 and S2. Of these tumors, 150 were subjected to targeted exome sequencing (TES) (Supporting Table S1 ), performed using the 48-gene TruSeq Amplicon Cancer Panel (Illumina). The remaining 15 cases underwent whole-exome sequencing (WES) (Supporting Table S2 ) and were analyzed alongside 262 publically available WES iCCA samples (Supporting Table S3 ).
SINGLE-NUCLEOTIDE VARIANT CALLING AND ANALYSIS
FASTQ files were filtered, subjected to quality control, and mapped to the human genome assembly (hg19) using BWA software. Single-nucleotide variants (SNVs) and short indels were called using a combination of Varscan (v2.3), somaticSnipper (v1.0.4), and Shimmer. Annovar was used to classify SNVs as synonymous or nonsynonymous. Potential impacts of amino acid alterations on protein structure and function were assessed by PolyPhen-2. Motif enrichment analysis was performed by HOMER. Inference of mutational signatures was carried out with the SomaticSignatures tool. Pathway enrichment of significantly mutated genes encoding SNVs and indels was assessed using genome MuSiC. Further information regarding bioinformatics analysis can be found as Supporting Information.
FGFR2 FUSION DETECTION
In total, 122 of 150 tumors subjected to TES were assessed for known FGFR2 fusions. RNA were isolated and subjected to reverse transcription with the SuperScript VILO cDNA Synthesis kit (ThermoFisher Scientific). Fusion products in FGFR2 were targeted with primer pairs flanking breakpoints of FGFR2 and previously reported donor genes. Commercially synthesized DNA with FGFR2 and all known fusion partner sequence fragments (Integrated DNA Technologies) were cloned into plasmid scaffolds and used as positive controls. Fusions were confirmed by Sanger sequencing. Further information regarding fusion detection can be found as Supporting Information.
CELL CULTURE
CCA cell lines were purchased from KCLB (SNU-478, SNU-1079, SNU-1196), DSMZ (EGI-1), and RIKEN (HuCCT-1, RBE) and obtained from the Mayo Clinic (WITT, KMCH). Cells were cultured in Rowell Park Memorial Institute 1640 or Dulbecco's modified Eagle's medium F12 (ThermoFisher Scientific), all supplemented with 10% heat-inactivated fetal bovine serum (GE Healthcare), 1% penicillinstreptomycin, and 1% L-glutamine (ThermoFisher Scientific). Cells were maintained at 378C and 5% CO 2 .
HIGH-THROUGHPUT DRUG REPOSITIONING
Drug screening was carried out using a drug library of 525 compounds (Food and Drug Administrationapproved or in late-stage clinical trials). Cells were seeded into 384-well plates and treated for 72 hours over 5-fold dilution series. Antiproliferative cellular effects were measured with CellTiter-Glo Luminescent Cell Viability assay (Promega), per the manufacturer's instructions, and quantified using the drug sensitivity score (DSS) metric. (16) Further information regarding drug screening can be found as Supporting Information.
COPY NUMBER ALTERATION CALLING AND ANALYSIS
Copy number alterations (CNAs) were analyzed using VarScan2, DNAcopy, and GISTIC2 packages. FGFR2 fusions were predicted using BreakDancer. Further information regarding CNA analysis can be found as Supporting Information.
GENOME-WIDE DNA METHYLATION PROFILING
In-house and publically available Infinium Human Methylation 450k BeadChip (Illumina) data were used to identify an independent patient cohort (n 5 69) to investigate effects of classifier genes on DNA methylation profiles. Data were processed and analyzed using RnBeads (v1.2.1). Further information regarding methylomics can be found as Supporting Information.
Results
RATIONAL IDENTIFICATION OF CLASSIFIER MUTATIONS FOR iCCA PATIENT STRATIFICATION
To investigate mutational diversity in iCCA, we analyzed 427 patients by TES (TES cohort, n 5 150 patients) and WES (WES cohort, n 5 277 patients, incorporating 142 tumor/normal matched pairs and 135 tumors) (17) (18) (19) (20) (21) ) (Supporting Fig. S1A ,B). Analysis of the TES cohort of 48 cancer-related genes (Supporting Table S1 ) revealed IDH1 (n 5 21/150; 14%), TP53 (n 5 19/150; 13%), and KRAS (n 5 18/150; 12%) as the most recurrent mutations ( and KRAS (G12A/C/D) were recurrent hotspots, while TP53 mutations were distributed throughout the gene body ( Fig. 1C ) with prevalent R249S (n 5 10/ 45; 22.2%) mutations. Importantly, co-occurrence of IDH1/KRAS mutations (TES cohort, n 5 1/150; 0.7%; WES cohort, n 5 1/277; 0.4%) and IDH1/ TP53 mutations (TES cohort, n 5 3/150, 2%; WES cohort, n 5 1/277, 0.4%) was rare, suggesting mutual exclusivity (Fig. 1A,B) . In comparison, dual mutations in KRAS and TP53 are detected in a subset of patients (TES cohort, n 5 4/150; 2.7%; WES cohort, n 5 14/ 277; 5.1%) but are not mutually inclusive (P 5 0.07, Fisher's exact test). Accordingly, we stratified iCCA patients into four groups (gr) based on mutational status of these genes, referring to them as IDH-gr (including IDH1 and IDH2 mutations), KRAS-gr, TP53-gr, and Udt-gr (wild type for all three driver genes).
FGFR2 fusion events have been identified in 5.5% (21) to 28% (10) of patients, implicating this event as one of the most recurrent genomic alterations in iCCA. We next analyzed the prevalence of fusions in the TES cohort by performing targeted analysis against known fusion partners, followed by confirmation with Sanger sequencing. We observed that 14.8% (n 5 18/ 122) of tumors were FGFR2-BICC1 fusion-positive, where 83.3% (n 5 15/18) cases fused with BICC1 in exon 3 and the remaining 16.7% (n 5 3/18) fused in exon 5 (Supporting Fig. S2A,C) . Clinically, FGFR2 fusion-positive status was associated with shorter overall survival (P < 0.0001; Supporting Fig. S2D ). The majority of fusion events (n 5 12/18; 66.7%) fell within Udt-gr. Similarly, in previously reported FGFR2 fusions from RNA-sequencing data (n 5 117/ 277; 42.2%; Japanese patients), FGFR2 fusions are predominant in Udt-gr (n 5 3/4; 75%) (Supporting Fig. S2B ).
Focusing on tumor/normal matched cases (n 5 142/277; 51.3%), we annotated 7,921 nonsynonymous SNVs in 5,457 genes (Supporting Table S4 ) and 2,581 synonymous SNVs in 2,229 genes (Supporting Table  S5 ) with an average of 2.3 mutations/Mb (Fig. 1D) . Apart from the prevalent mutant classifiers (IDH, KRAS, and TP53), other significantly mutated genes include chromatin modifiers (ARID1A, BAP1, KDM6B, and SETD2) and genes newly associated with iCCA (Fig. 1E) . We next analyzed known clinical risk factors associated with mutational subgroups and observed that HBV infection was significantly associated with TP53-gr (n 5 26/45; 58%; P 5 1.612 3 10 -5 , Fisher's exact test) (Fig. 1E) . Interestingly, HBV was also associated with a large number of Udtgr tumors (n 5 21/63; 33%) but did not reach significance when compared to the entire cohort (Fig. 1E) . However, no significant association was determined between mutational subgroups and diabetes mellitus, smoking, or alcohol consumption.
MUTATION-CENTRIC TUMOR STRATIFICATION IDENTIFIES DIVERSE ONCOGENIC PROCESSES
The mutational signatures defined by immediate 5 0 and 3 0 sequences flanking SNVs may reflect specific underlying mutagenic processes (22) ; thus, we investigated mutagenic signatures associated with the four subgroups. Though C>T transitions and C>A transversions are prevalent overall in iCCA (Supporting Fig. S3A ), as described, (20, 21) mutational signatures are unique between subgroups ( Fig. 2A) . IDH-gr displayed a specific enrichment of C>A transversions (67%, P 5 7.01 3 10 -132 ) (signature 18, 28) ( Fig.  2A,B ). As such, C>A transversions have been associated with oxidative stress, (23) complementing previous studies characterizing the physiological role of wildtype IDH1 in protecting hepatocytes from oxidative stress. (24) KRAS-gr was characterized by predominant C>T transitions ( Fig. 2A ) (55%, P 5 3.40 3 10 -87 , Fisher's exact test), displaying a preference for purine (G or C) upstream of transitions (Fig. 2B) and suggesting a role for APOBEC (signature 2 and 13). (22) Also, promoters of genes mutated in KRAS-gr were enriched for FOSL2 motif binding sites (Supporting Fig. S4 ), in agreement with the transcriptional signature derived from KRAS-driven tumors. (25) TP53-gr displayed preferential unique T>A transversions (26%, P 5 2.29 3 10 -125 ), with NpT>ApG associated with aristolochic acid (signature 22). Although a significant enrichment of R249S mutations was detected in TP53-gr (Fig. 1C) , the aflatoxin signature was not enriched as in hepatocellular carcinoma. Also, R249S did not display a significant relationship with HBV status (P 5 0.48, Fisher's exact test) or overall survival (P 5 0.917) when comparing with patients manifesting other TP53-specific mutations.
Akin to IDH-gr, Udt-gr displayed a preference for C>A transversions (42%, P 5 4.69 3 10 -10 ). In fact, nonmatrix factorization clustering of signature contributions across mutation subgroups in patients and CCA cell lines (n 5 16) indicated a close association between IDH-gr and Udt-gr (Supporting Fig. S3B,  C) . Such similarity was also observed at the transcriptome level in our previously published cohort (26) through hierarchical clustering of significant differentially expressed genes (F test, P < 0.001; Supporting  Fig. S3D ). Taken together, these findings suggest that without patient stratification, Udt-gr would have masked the unique genetic patterns elicited by IDHgr, KRAS-gr, and TP53-gr. Furthermore, these data indicate that the diversity of oncogenic programs (unique and shared between subgroups) may arise early in tumorigenesis from their initial genetic mutational signatures and possibly transcend different genomic readouts in their consequences.
INTERGROUP MUTATIONAL ANALYSIS UNCOVERS UNIQUE COMUTATIONAL PROFILES
Next, we analyzed the extent of exclusivity of mutated genes among subgroups and observed that the majority of genes encoding nonsynonymous SNVs were unique (Fig. 3A) and co-occurred (two or more tumors) within their individual subgroups ( Fig. 3B,C ; Supporting Table S6A-D) . Genes encoding somatic synonymous SNVs were also unique to each subgroup (Supporting Fig. S5A and Table S6E ) but showed minimal overlap (2%-4%) (Supporting Fig. S5B ) with nonsynonymous SNV genes, suggesting that these mutational processes are dissimilar. Furthermore, somatic synonymous SNVs have a low recurrence rate and lack significantly mutated genes with iCCA subgroups (Supporting Fig. S5C ), which is markedly different from nonsynonymous mutated genes (Fig. 3C) .
As expected, IDH1, KRAS, and TP53 were the most significantly altered genes in their respective groups along with specific enrichment of BCLAF1 (P 5 0.007) in IDH-gr; SMAD4 (P 5 0.03) in KRAS-gr; PTEN (P 5 9.36 3 10 and LATS2 (P 5 0.02) in TP53-gr; and KDM6B in Udt-gr (P 5 0.08) ( Fig. 3C ; Supporting Table  S7 ). Among the previously reported chromatin modifier genes, ARID1A mutations were present in IDH-gr, KRAS-gr, and Udt-gr but only significantly enriched with Udt-gr tumors (P 5 8.86 3 10 ). Notably, no chromatin modifiers were associated with TP53-gr. The association of significantly mutated genes along with the three classifier genes are represented in Fig. 3D .
We next evaluated any prognostic significance across four mutational subgroups. In the WES cohort of 142 tumor/normal patient samples, KRAS-gr and TP53-gr were significantly associated with poor overall survival (P 5 0.003; Fig. 3E ) and faster time to recurrence (P 5 0.018; Fig. 3F ). These findings were confirmed in two independent cohorts, where KRAS-gr was associated with worse overall survival in the TES cohort (n 5 150) (P 5 0.0004; Fig. 3G ) and both KRAS-gr and TP53-gr were correlated with worse overall survival (P 5 0.0001; Fig. 3H ) in the Nakamura et al. cohort (n 5 135).
(21) Thus, we conclude that these four mutational subgroups have a distinct association of comutated genes and different overall survival.
iCCA SUBGROUPS HARBOR UNIQUE DYSREGULATED PATHWAYS THAT ARE REFLECTED IN THEIR DRUG-RESPONSE PROFILES
To understand whether genes associated with each subgroup could contribute to different oncogenic programs through tailored pathway dysregulation, we analyzed perturbed pathways associated with each group (Fig. 4A,B ; Supporting Table S8 ). IDH-gr was enriched for metabolic pathways, including glutathione metabolism (P 5 6.33 3 10 -21 ) and the citrate cycle (P 5 2.37 3 10 -14 ), which is consistent with the known involvement of IDH1 in metabolic processes in CCA. (27) KRAS-gr was highly enriched for various immune-related pathways, including ErbB (P 5 4.39 ) were enriched in TP53-gr. Because mutations in KRAS and TP53 occur in a small subset of patients, pathway enrichment in dual mutants was independently assessed. Notably, significantly enriched pathways were all present in either KRAS-gr or TP53-gr (Supporting Table S8 ), supporting our previous inclusion of these patients in both KRAS-gr and TP53-gr analyses. Finally, despite being the largest group, Udt-gr was exclusively enriched for mammalian target of rapamycin signaling (P 5 4.76 3 10 -3 ), suggesting that Udt-gr is highly heterogeneous with regard to SNVs. To indirectly test the validity of our classifier genes, we selected the next three most recurrent mutated genes as alternative classifiers: ARID1A-gr (n 5 14; 9.9%), CDC27-gr (n 5 12; 8.5%), and BAP1-gr (n 5 9; 6.3%), as well as Remaining-gr (n 5 110; 77.5%; analogous to Udt-gr) (Supporting Fig. S6 ). No pathways were uniquely enriched among these surrogate groups, with significant biological processes emerging only in the "remaining" tumors, thus justifying our patient classification.
Next, we sought to determine whether mutational subgroups displayed differential sensitivity to diverse classes of compounds in vitro and whether these drug responses reflected in silico predictions of enhanced pathway dysregulation. To determine the "best fit" cell models, mimicking the patient groups, we earlier performed nonmatrix factorization clustering of the mutational signatures (genetic substitution patterns) in patients and a panel of 16 CCA cell lines (Supporting Fig. S3B,C) . This confirmed that genetic signatures under our mutational classifiers were comparable between cell lines and patients.
Accordingly, we selected seven cell lines with matched mutational profiles representative of each of the patient subgroups, as well as one mixed mutant cell line (RBE; KRAS G12V and IDH1 R132S ) not observed in patients (Supporting Table S9 ). Each cell line was subjected to high-throughput screening using a drug library of 525 late-stage trial/Food and Drug Administration-approved compounds at clinically achievable tissue concentrations (Fig. 4C) . We classified compounds as biologically active (DSS > 10) or inactive (DSS < 10) (16, 28) and then linked them to the mutational subgroup in which maximal therapeutic effect was observed ( Fig. 4D ; Supporting Table S9 ). RNA synthesis inhibitors (P 5 0.029, Fisher's exact test), microtubule-targeting drugs (P 5 2.93 3 10 -4 ), topoisomerase inhibitors (P 5 1.1 3 10 -3 ), PLK1 inhibitors (P 5 0.018), and mammalian target of rapamycin pathway modulators (P 5 7 3 10 -6
) displayed maximal efficacy in IDH-gr, KRAS-gr, TP53-gr, and Udtgr, respectively. These modalities largely support earlier observed subgroup-enriched pathway dysregulation (Supporting Table S8 ) as therapeutic vulnerabilities in iCCA. The top 21 most effective drugs with specific mutational subgroup enrichment are depicted in Fig.  4E . Notably, the presence of dual mutations appears to abrogate such observed sensitivities in the RBE cell line (mixed). Taken together, these experimental findings support the concept of preferential pathway deregulation, governed by our mutational subclassification, which may have important implications for exploitation of pharmacological vulnerabilities.
STRUCTURAL AND EPIGENOMIC BURDEN VARY ACROSS iCCA PATIENT SUBGROUPS
In SNVs, Udt-gr tumors showed limited enrichment of specific pathways. This suggests either substantial molecular heterogeneity within Udt-gr or that the causality is related to other genome features (gene fusion, recurrent somatic CNA [SCNA], or epigenetics). We analyzed enriched SCNA segments (total counts) and observed that IDH-gr has the lowest, followed by KRAS-gr, Udt-gr, and TP53-gr ( Fig. 5A ; Supporting Table S10 ). Frequencies of SNV and SCNA segments exhibit an inverse trend (Fig. 5B) , similar to observations in other cancers (29) with enrichment of DNA repair mismatch genes in cases with high mutational burden. As such, KRAS-gr and IDH-gr have few recurrent focal SCNAs, while TP53-gr and Udt-gr tumors have a comparably higher frequency of recurrent structural variants (and encoded genes) (Supporting Fig. S7A and Table S10 ). Recurrent deletions were significant across all four groups, while recurrent amplifications were only significant in TP53-gr and Udt-gr (Fig. 5C ). The majority of recurrent SCNA segments were unique to each group (Supporting Fig. S7B and Table S11 ). The only common cytoband 9p21.3 enriched across all groups was the but found no significant correlation (Supporting Fig.  S7C-G) .
Genes within focal SCNA peaks were highly recurrent (70%-90% of patients) in their respective subgroups ( Fig. 5D ; Supporting Table S11), suggesting potential causal roles in their pathogenesis. We performed pathway analysis across each subgroup and identified IDH-gr and TP53-gr as largely silent ( Fig.  5E ; Supporting Table S12), suggesting a diminished contribution of structural variants to their pathogenesis. In contrast, KRAS-gr showed enrichment of multiple immune-related processes (natural killer cytotoxicity, Janus kinase/signal transducer and activator of transcription, and cytokine signaling), complementing our findings from SNVs of widespread immune pathway subversion in these patients (Fig.  4A ). Similar enrichment of structural alterations in immune pathway genes (related to viral and/or bacterial infection) was also found in Udt-gr, a patient subgroup with a heterogeneous low SNV burden but high SCNA frequency.
To investigate epigenomic contributions to cholangiocarcinogenesis, we classified an independent iCCA patient cohort (n 5 69; Supporting Table S13) (11, 13) into our four mutational subgroups and compared differential DNA methylation profiles relative to surrounding normal tissues. Consistent with our earlier cohorts ( Fig. 3E-H) , KRAS-gr was again associated with decreased overall survival within 12 months following surgery (Fig. 6A) . While all subgroups displayed predominant hypermethylation over hypomethylation across promoters and gene bodies, the total burden of differentially methylated regions (DMRs) varied between subgroups ( Fig. 6B ; Supporting Table  S13 ). Unsurprisingly, given its role in DNA demethylation, IDH-gr displayed the greatest number of DMRs (n 5 2,499/2,646; 94.4% hypermethylation). Notably, Udt-gr harbored the next most extensive DNA methylome alterations. Such findings were also emphasized in pathway enrichment, where KRAS-gr and TP53-gr were largely silent and Udt-gr was particularly enriched in neuron-related signaling ( Fig. 6C ; Supporting Table S14 ). Given the fact that the copy number status has been reported to have little effect on DNA methylation alterations, (30, 31) here we demonstrate an additional independent molecular pathomechanism that may positively affect iCCA subtypes and influence tumor behavior as well as therapeutic response.
The most recurrent focal SCNA segment in Udt-gr includes the gene methyltransferase-like 13 (METTL13), which is amplified in 70% of patients (Fig. 5D) . Comparison of its structural alteration across 36 tumor types (The Cancer Genome Atlas) revealed it to be most frequently amplified in CCA (Supporting Fig. S8A ), correlating with elevated gene expression and DNA methylation (Supporting Fig.  S8B-D) . Given METTL13's expected role as an S-adenosyl methionine methyltransferase, we tested whether this patient subgroup (METTL13 amp) was readily distinguishable at the epigenetic level and established a DNA methylation signature that efficiently distinguishes it from surrounding normal tissues and its parent Udt-gr (Fig. 6D) . Patients harboring METTL13 amplification display greater overall survival (P 5 0.00033; Fig. 6E ). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of METTL13 amplification-unique DMRs revealed enrichment of transcriptional control and kinase signaling pathways (Fig. 6F ). As such, METTL13 amplification could potentially contribute to the elusive pathogenicity of Udt-gr tumors (Supporting Fig. S8 ).
Discussion
Arguably the greatest obstacle in the development of therapeutic strategies for CCA is its extensive molecular heterogeneity, further confounded by mixed patient cohorts of varied clinical and pathological features. Previous efforts have identified individual genomic events responsible for specific therapeutic sensitivities (e.g., IDH mutations (14, 15) and FGFR2 fusions (10) ) and broad clusters of patients with diverse characteristic pathobiological properties. (11) (12) (13) What remains unclear are the broader network implications of such individual events and the molecular origins of these clusters. Here, we highlight the potential of the three most recurrent SNVs (IDH, KRAS, TP53) to direct unique oncogenic programs in iCCA and, in turn, expose a subset of their network-based vulnerabilities (Fig. 7) . Furthermore, we uncover enhanced roles of structural and epigenomic perturbation mechanisms in patients lacking mutations in these three classifier genes, reinforcing the need for integrative approaches to comprehensively stratify patients.
In both TES (n 5 150) and WES cohorts (n 5 277), the top three recurrently mutated genes were found to be TP53, KRAS, and IDH1, as anticipated. (17, 20, 21) Intriguingly, these three classifier genes are highly distinct with regard to their role in oncogenesis and, as highlighted in this study, in cholangiocarcinogenesis. Hotspot mutations in KRAS (G12A/C/ D) play a significant role in iCCA initiation in mouse models (32) and are associated with a proliferation subgroup of patients with poor prognosis. (26, 33) Mutational inactivation of tumor suppressor TP53 contributes to this tumor formation in vivo (32) and was previously correlated with hypermutated patient tumors. (21) Unlike KRAS, no mutational hotspot exists in TP53, and different mutations in this gene have been shown to generate diverse neomorphic mutants with varied cellular effects (reviewed in Freed-Pastor and Prives (34) ), indicating the potential for additional network heterogeneity within this subgroup. Functionally nonsynonymous hotspot mutations in IDH1 (R132) and IDH2 (R172) promote cholangiocarcinogenesis through repression of hepatocyte differentiation. (35) However, mutation of these metabolic enzymes has broad cellular implications as aberrant downstream metabolites impair the function of approximately 20 enzymatic families (only one of which is involved in DNA methylation regulation).
Given the diverse nature of these three mutational events, we anticipate diverse network consequences downstream. Prediction of the sufficiency of three mutations to induce invasive carcinoma, (36) however, reinforces the missing molecular pathogenicity garnered through use of single-gene dissection of tumors. Here, we have highlighted the unique comutational spectra associated with each of the classifier genes. Interestingly, while KRAS and IDH mutations are mutually exclusive, KRAS and TP53 mutations coexist in a small subset of patients. Such mutations may be complementary in a minority of patients, given their opposing nature as oncogenes and tumor suppressors or potentially if they arise at different times during cellular transformation. Indeed, KRAS-gr and TP53-gr tumors share the greatest similarity in altered pathways. Nonetheless, these findings remain unaltered if KRAS/TP53 dual mutants are excluded, suggesting that such pathway similarity arises from a common underlying biology (such as cell cycle regulation) rather than inclusion of comutants. Additionally, our patient stratification does not take into account, though may subtly reflect, the heterogeneous cellular origins of iCCA. For example, given recent reports of IDH mutant (11) and "IDH-like" (37) hepatocellular carcinoma subgroups, this may indicate a putative common origin, further supporting the continuous spectrum of liver tumors. (38) Conversely, KRAS mutations are highly recurrent in pancreatic cancer (39) and perihilar CCA, potentially suggesting a more likely origin from peribiliary glands.
Initially, a limitation of our genomic stratification appeared to be the relatively large proportion of FIG. 7 . Mutation-centric diversity of cholangiocarcinogenesis. Incidence of SNV, recurrent SCNA, and DMRs across groups is shown as a relative ratio (scaled to 1). Integrating "omic" and pathway analysis, confirmed by in vitro drug testing, suggests enhanced activity of specific compounds in specific mutational subgroups. Abbreviation: mTOR, mammalian target of rapamycin.
